IMCRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Immunocore Holdings plc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$29.84+0.44 (+1.50%)
Close on Oct 19, 2026
- Market cap
- $1.52B
- P/E (TTM)
- –
- Dividend yield
- 0.00%
Immunocore statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | Immunocore | Industry median |
|---|---|---|
| Market Cap | $1.54B | $166.30M |
| Enterprise Value | $656.51M | $87.12M |
| PS Ratio | 3.57 | 3.60 |
| PB Ratio | 3.66 | 2.03 |
| P/TBV Ratio | 3.66 | 2.31 |
Enterprise value
| Measure | Immunocore | Industry median |
|---|---|---|
| EV / Sales | 1.52 | 2.43 |
Income (trailing twelve months)
| Measure | Immunocore | Industry median |
|---|---|---|
| Revenue | $430.78M | $57.94M |
| Gross Profit | $426.04M | $90.47M |
| Operating Income | -$22.58M | -$21.49M |
| Pretax Income | -$2.73M | -$14.72M |
| Net Income | -$18.07M | -$22.46M |
| EBITDA | -$22.58M | -$17.14M |
| EPS (Diluted) | -$0.36 | -$0.83 |
Margins
| Measure | Immunocore | Industry median |
|---|---|---|
| Gross Margin | 98.9% | 52.3% |
| Operating Margin | -5.24% | -44.5% |
| Pretax Margin | -0.63% | -13.0% |
| Profit Margin | -4.20% | -39.2% |
| EBITDA Margin | -5.24% | -31.3% |
| FCF Margin | -9.55% | -8.85% |
Returns
| Measure | Immunocore | Industry median |
|---|---|---|
| Return on Equity (ROE) | -4.47% | -53.2% |
| Return on Assets (ROA) | -1.64% | -41.0% |
| Return on Capital Employed (ROCE) | -2.55% | -38.0% |
Growth
| Measure | Immunocore | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 21.0% | 6.01% |
| FCF Growth (YoY) | -244.6% | 2.34% |
| Revenue Growth (3Y CAGR) | 31.9% | 2.25% |
Balance sheet
| Measure | Immunocore | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $880.21M | $62.64M |
| Net Cash (Debt) | $880.21M | $15.77M |
| Net Cash Per Share | $17.09 | $0.66 |
| Equity (Book Value) | $419.80M | $48.61M |
| Book Value Per Share | $8.15 | $1.36 |
| Tangible Book Value | $419.80M | $23.01M |
| Working Capital | $815.85M | $75.09M |
Financial position
| Measure | Immunocore | Industry median |
|---|---|---|
| Current Ratio | 4.47 | 3.30 |
| Quick Ratio | 3.74 | 2.39 |
| Interest Coverage | -1.85 | -7.12 |
Cash flow (trailing twelve months)
| Measure | Immunocore | Industry median |
|---|---|---|
| Operating Cash Flow | -$34.96M | -$12.39M |
| Capital Expenditures | -$6.20M | -$1.07M |
| Free Cash Flow | -$41.15M | -$20.34M |
| FCF Per Share | -$0.80 | -$0.42 |
Efficiency
| Measure | Immunocore | Industry median |
|---|---|---|
| Asset Turnover | 0.39 | 0.38 |
| Inventory Turnover | 0.72 | 2.67 |
| Revenue Per Employee | $822.09K | $398.96K |
| Profits Per Employee | -$34.49K | -$705.27K |
| Employee Count | 524 | 74 |
Dividends and yields
| Measure | Immunocore | Industry median |
|---|---|---|
| Earnings Yield | -1.18% | -22.8% |
| FCF Yield | -2.68% | -9.02% |
| Dividend Yield | 0.00% | 1.82% |
| Shareholder Yield | 0.00% | 0.00% |
| Dividend Per Share | $0.00 | $0.83 |
| Years of Dividend Growth | 0 | 0 |
Shares
| Measure | Immunocore | Industry median |
|---|---|---|
| Shares Outstanding | 51,498,600 | 58,139,000 |
| Shares Change (YoY) | -0.10% | 11.1% |
| Shares Change (QoQ) | 1.28% | 0.54% |
| Float | 43,526,900 | 49,154,900 |
| Shares Held by Insiders | 15.5% | 11.6% |
| Shares Held by Institutions | 101.8% | 59.4% |
Taxes
| Measure | Immunocore | Industry median |
|---|---|---|
| Income Tax | $15.34M | $89.00K |
Scores
| Measure | Immunocore | Industry median |
|---|---|---|
| Altman Z-Score | 1.49 | -0.27 |
| Piotroski F-Score | 3 | 4 |
Calculated by StockData from Immunocore's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.